Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine : A substudy of the NEAT001/ANRS143 randomised trial
Bernardino, J. I. (Hospital Universitario La Paz (Madrid))
Mocroft, Amanda (University College London)
Wallet, C. (University of Bordeaux)
De Wit, Stéphane (CHU Saint Pierre, Brussels)
Katlama, C. (Hôpital Pitié Salpétrière, Paris)
Reiss, Peter (University of Amsterdam)
Mallon, P. W. (University College Dublin)
Richert, L. (University of Bordeaux)
Molina, J. M. (University of Paris Diderot)
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya))
Morlat, Philippe (CHU Bordeaux)
Babiker, A. (University College London)
Pozniac, A. (Chelsea and Westminster Hospital NHS Foundation Trust)
Raffi, F. (CHU de Nantes)
Arribas, Jose (Hospital Universitario La Paz (Madrid))
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Background Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. Design Randomised Clinical Trial. Methods This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) in 805 ART naïve HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). Results 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1. 5% per 48-week period (p = 0. 015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2. 5% (p = 0. 38), 7. 3% ((p = 0. 021), 4. 9% (p = 0. 061) and 1. 3% (p = 0. 12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0. 31 (p = 0. 0043)/r = 0. 28 (p = 0. 0011) for limb fat, and r = 0. 63 (p<0. 0001)/r = 0. 50(p<0. 0001) for trunk fat]. After adjustment, a 10% faster increase in leptin between baseline and week 48 was associated with a more rapid increase in limb fat at week 48 (0. 5% per 48 weeks, p<0. 001), total body fat mass (0. 6% per 48 weeks, p<0. 001), and trunk fat mass (0. 3% per 48 weeks, p = 0. 0026). Conclusions After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater percentage increase in body composition variables with only change in trunk fat mass and BMI being significant.
Ajuts:	European Commission LSHP-CT-2006-037570
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adipokines ; Adult ; Body Composition ; Body Mass Index ; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination ; Female ; Humans ; Male ; Raltegravir Potassium ; Time Factors
Publicat a:	PloS one, Vol. 14 Núm. 1 (january 2019) , p. e0209911, ISSN 1932-6203

DOI: 10.1371/journal.pone.0209911
PMID: 30689664

13 p, 1.2 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats